Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone Sustained-release Tablets for Moderate to Severe Cancer Pain
CTR20202609Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydromorphone in cancer pain, sponsored by Yichang Humanwell Pharmaceutical Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on CTR20202609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202609.